• To demonstrate the safety and tolerability of SC administered Gamunex [ Time Frame: 6 months ] [ Designated as safety issue: No ]
• AUC 0-7 days following the weekly SC infusion, i.e., the AUC over a weekly SC dosing interval under an approximate steady-state condition. [ Time Frame: 17 weeks ] [ Designated as safety issue: No ]
• AUC 0-28 days following the monthly IV infusion, i.e., the AUC over a monthly IV dosing interval under an approximate steady-state condition. [ Time Frame: 1 month ] [ Designated as safety issue: No ]

• To demonstrate the safety and tolerability of SC administered Gamunex
• AUC0-7 days following the weekly SC infusion, i.e., the AUC over a weekly SC dosing interval under an approximate steady-state condition.
• AUC0-28 days following the monthly IV infusion, i.e., the AUC over a monthly IV dosing interval under an approximate steady-state condition.
• To demonstrate non-inferiority in steady-state AUC of plasma IgG from weekly subcutaneous doses of Gamunex as compared to that from monthly intravenous doses of Gamunex
• To assess the incidence of serious bacterial infections in subjects treated with SC administered Gamunex

This study will compare the blood level of Gamunex in patients. Patients will take it as an injection under the skin or in a vein. The study will compare how safe and tolerable the two methods are in the patients. The patients in this study have a defect in their immune system from a genetic cause.

This is an open-label, single-sequence, multi-center trial with subjects previously diagnosed with primary immune deficiency. Subjects will be on IGIV until until a steady state is reached at which time PK profiling during the IV phase will occur. Subjects will begin SC administration 1 week following last IV dose and followed for a period of six months. PK profiling in SC phase will occur when subject reaches approximate steady-state on SC administration.

Inclusion Criteria:

• Adults and adolescents (age 13-75 inclusive) with a documented and confirmed pre-existing diagnosis of chronic primary immune deficiency
• Previously or currently on IgG replacement therapy
• Documented (within 3 months) plasma IgG level of >500 mg/dL on current IgG therapy (IgG level can be obtained at the screening visit if documentation is not available)
• The medical records for all subjects within the previous 2 years should be available to document previous infections and treatment

Exclusion Criteria:

• Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial
• The subject has a known adverse reaction to Gamunex or other blood products
• The subject has a history of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections or other disorders where subcutaneous therapy would be contraindicated
• The subject has known selective IgA deficiency with the exception of a known IgA deficient subject who has no previous documented eventful reaction to products containing IgA
• The subject is pregnant or lactating
• The subject has significant proteinuria and/or has a history of acute renal failure and /or severe renal impairment (BUN or creatinine more than 2.5 times the upper limit of normal) and/or on dialysis
• The subject has known substance or prescription drug abuse in the past 12 months
• The subject has a history of or current diagnosis of deep venous thrombosis
• The subject has an acquired medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000 x 10e9/L), or HIV infection/AIDS
• The subject is receiving any of the following medications: corticosteroids (long-term daily, >1 mg of prednisone equivalent/kg/day for >30 days) (intermittent courses would not exclude subject); immunosuppressants; or immunomodulators
• The subject has non-controlled arterial hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg)
• The subject has anemia (hemoglobin <10 g/dL) at screening
• The subject has participated in another clinical trial within 30 days prior to screening (imaging studies without investigative treatments are permitted) or has received any investigational blood product within the previous 3 months